Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for PrAJOVY® ...
Initiation of calcitonin gene-related peptide inhibitors for migraine is linked to a small increased risk for a composite of ...
MedPage Today on MSN
Next-gen Alzheimer's therapy; CGRP drugs' heart risks; MS role on 'Grey's Anatomy'
News and commentary from the world of neurology and neuroscience ...
A statistically significant reduction in the mean number of monthly headache days (vs baseline) was observed for the CGRP-targeted therapies and propranolol ...
Meloxicam/Rizatriptan Effective in Migraine Patients With Inadequate Response to Oral CGRP Inhibitor
Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...
Amazon S3 on MSN
What really causes migraines? It’s not what you think
Migraines affect more than a billion people worldwide, yet they remain one of the most misunderstood neurological conditions.
Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating ...
Direct calcitonin gene-related peptide with monoclonal antibody exposure was also associated with significantly reduced rates of acne and rosacea compared with topiramate. HealthDay News — For ...
The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...
Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results